No supplier or customer ties in NXTC's filings yet. The map draws only what companies disclose to the SEC; ties named in other companies' filings join as the graph reads them.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
No earnings record for NXTC on the current feed.
Nothing on the wire mentions NXTC yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How NXTC has moved on past release days vs its typical ±4.3% day, and how often it closed up. Computed from daily closes — not a forecast.